Marietta Investment Partners LLC Sells 52,728 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Marietta Investment Partners LLC reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 76.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,401 shares of the biopharmaceutical company's stock after selling 52,728 shares during the period. Marietta Investment Partners LLC's holdings in Halozyme Therapeutics were worth $784,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of HALO. CBIZ Investment Advisory Services LLC acquired a new stake in Halozyme Therapeutics in the fourth quarter worth $29,000. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC increased its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares during the last quarter. Venturi Wealth Management LLC acquired a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 0.6 %

HALO traded up $0.40 during trading hours on Tuesday, hitting $64.42. 417,555 shares of the company's stock were exchanged, compared to its average volume of 1,386,928. The stock has a market cap of $7.96 billion, a price-to-earnings ratio of 18.78, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The stock's 50-day moving average is $58.39 and its two-hundred day moving average is $54.68. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock worth $1,754,451 over the last 90 days. Company insiders own 2.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Benchmark reiterated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research report on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.